Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.
about
Enhanced Specificity and Drug Delivery in Tumors by cRGD-Anchoring Thermosensitive LiposomesNANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer?Designer lipids for drug delivery: from heads to tails.Lipid-shelled vehicles: engineering for ultrasound molecular imaging and drug deliveryRecent trends in multifunctional liposomal nanocarriers for enhanced tumor targetingNovel Methods of Enhanced Retention in and Rapid, Targeted Release from Liposomes.Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity.A generic 89Zr labeling method to quantify the in vivo pharmacokinetics of liposomal nanoparticles with positron emission tomography.Transient cerebral hypoperfusion assisted intraarterial cationic liposome delivery to brain tissue.An optical and microPET assessment of thermally-sensitive liposome biodistribution in the Met-1 tumor model: Importance of formulation.The role of pH and ring-opening hydrolysis kinetics on liposomal release of topotecan.Positively-charged, porous, polysaccharide nanoparticles loaded with anionic molecules behave as 'stealth' cationic nanocarriersLiposomal nanostructures for photosensitizer delivery.PLGA/liposome hybrid nanoparticles for short-chain ceramide deliveryInterpatient pharmacokinetic and pharmacodynamic variability of carrier-mediated anticancer agents.Copper-doxorubicin as a nanoparticle cargo retains efficacy with minimal toxicity.Paramagnetic liposomes for molecular MRI and MRI-guided drug delivery.Cerebral hypoperfusion-assisted intra-arterial deposition of liposomes in normal and glioma-bearing rats.Release, partitioning, and conjugation stability of doxorubicin in polymer micelles determined by mechanistic modeling.Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenograftsIron complexation to histone deacetylase inhibitors SAHA and LAQ824 in PEGylated liposomes can considerably improve pharmacokinetics in rats.Design and in situ characterization of lipid containers with enhanced drug retention.The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents.An in vitro assessment of liposomal topotecan simulating metronomic chemotherapy in combination with radiation in tumor-endothelial spheroids.Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle.Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine.Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine.Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB/c mice.Photodynamic therapy with conventional and PEGylated liposomal formulations of mTHPC (temoporfin): comparison of treatment efficacy and distribution characteristics in vivoCharacterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastineRole of in vitro release models in formulation development and quality control of parenteral depots.Nanomaterial standards for efficacy and toxicity assessment.Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology.Crosslinked multilamellar liposomes for controlled delivery of anticancer drugsLipid nanoparticles for the delivery of poorly water-soluble drugs.Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications.Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs.Innovative approaches for demonstration of bioequivalence: the US FDA perspective.Strategies for triggered drug release from tumor targeted liposomes.Liposomal antibiotics for the treatment of infectious diseases.
P2860
Q27314854-3DCCF1DE-FF7D-4AC1-AA5F-DE1B3D3183E6Q28078448-26C47277-8C95-4753-A3D0-BC9789FD79C2Q30402374-F217A21E-7ED7-45E4-9E76-5E64BB9276E8Q30435430-D8F4F093-6821-438D-B30A-70E0F23704B3Q30456053-97ED312C-4C9C-4DBC-9578-5649C0F951EAQ30466993-8B7EC510-A2E9-4E2D-AA20-67D354A218D2Q33598842-4DD5411C-98E7-40DC-8BFB-C05F46FE4F72Q33601723-0E20CDDF-1DEE-4AD3-9663-6764DCEE2B15Q33686848-4609326A-A5AF-485F-A004-1DF0F4E86654Q33818246-8273C85E-773A-4B17-B1DE-6CF4985593F6Q33925422-DC72592D-7FBF-4BAC-998A-3F7C9329DFFAQ33982639-B0428886-7074-481B-8343-84C6F97AAF39Q34068206-7CC3FB1D-AEDA-4048-9A0A-C1DC01FC2473Q34181875-807BF7DA-2ADB-4BF7-AA81-2F34BD097070Q34265621-E63C4FFE-BABD-470B-9E89-84F998B71B8BQ34566961-EA2D4DE0-6CD9-4419-8AF8-489AFEF1C07BQ34736942-0DB4E0C1-5890-4C04-B709-11262E6089D4Q34756425-CF6407AA-6F0A-476D-BA0D-6A471A73AA43Q35243546-CE7584E6-FF44-4846-9B1A-C2D2A3006E47Q35570265-F7B43778-BFF3-45CB-BA50-01045781D734Q36028325-B31A75A7-B323-41E2-9B18-80A86C5F2AEFQ36124777-825CC5E2-3EF7-49D2-9131-13DE97434FF8Q36126057-C34DCC68-AA05-44AF-9CDF-5463574EFE32Q36163874-CAC12818-1B52-4E74-98D5-A32D42D763E6Q36212921-4CAB9E57-335F-4030-B337-151A6AA6EBDEQ36629939-D00B3786-AA96-4D23-A38B-D18509D6503AQ37201370-CDC374B9-EB69-48CC-A6D9-FD94F7CDF705Q37204262-7C0047E3-82EE-4A3E-BE06-B5557E4C3CE6Q37231221-8EBF03FB-84E5-4E10-B929-5C28B91EACACQ37279686-A21A7CFE-04C1-4AC9-AF82-FAE4FE654201Q37639309-2D7F992E-89A0-4F9C-8292-D395B360F570Q37668451-EDC8516C-4F58-4F86-A466-2B6AD92C8652Q37689857-AFB76545-8F0C-4732-AE1D-50001BD4F52DQ37716771-4D96DD3D-C154-4166-8F31-7112FCC5C396Q37805594-5B9AA4AE-59D5-4AA8-943E-EE6C66962941Q37947952-72B0DD71-CB27-493A-87A6-E1678000FB7EQ37983912-20F588BD-A087-457F-A531-B72787B6ED07Q38112172-393BC5FB-31AB-4240-81AC-D771FECD293FQ38116638-2D83AAAD-620E-487A-9422-C7002A0D0E79Q38124144-80E639C5-A8CB-4F64-8AE5-95422572FBEE
P2860
Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.
@en
Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.
@nl
type
label
Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.
@en
Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.
@nl
prefLabel
Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.
@en
Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.
@nl
P2093
P356
P1476
Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.
@en
P2093
Charles O Noble
Daryl C Drummond
John W Park
Mark E Hayes
P304
P356
10.1002/JPS.21358
P407
P577
2008-11-01T00:00:00Z